Victory Capital Management Inc. Sells 138,406 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Victory Capital Management Inc. decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 57.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 102,411 shares of the company's stock after selling 138,406 shares during the period. Victory Capital Management Inc. owned approximately 0.17% of Protagonist Therapeutics worth $4,953,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Bank of Montreal Can boosted its stake in Protagonist Therapeutics by 4.5% during the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock valued at $241,000 after buying an additional 270 shares during the period. GF Fund Management CO. LTD. boosted its stake in Protagonist Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company's stock valued at $74,000 after buying an additional 275 shares during the period. GAMMA Investing LLC boosted its stake in Protagonist Therapeutics by 153.3% during the first quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock valued at $58,000 after buying an additional 728 shares during the period. WINTON GROUP Ltd boosted its stake in Protagonist Therapeutics by 3.0% during the fourth quarter. WINTON GROUP Ltd now owns 26,768 shares of the company's stock valued at $1,033,000 after buying an additional 785 shares during the period. Finally, State of Wyoming boosted its stake in Protagonist Therapeutics by 11.9% during the fourth quarter. State of Wyoming now owns 7,832 shares of the company's stock valued at $302,000 after buying an additional 832 shares during the period. Institutional investors own 98.63% of the company's stock.

Insider Activity

In other news, insider Arturo Md Molina sold 10,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total value of $570,300.00. Following the transaction, the insider owned 83,892 shares in the company, valued at approximately $4,784,360.76. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 22,065 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $55.05, for a total value of $1,214,678.25. Following the completion of the transaction, the chief executive officer owned 548,538 shares in the company, valued at approximately $30,197,016.90. This represents a 3.87% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,444 shares of company stock worth $3,450,344. Company insiders own 4.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on PTGX shares. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Citigroup began coverage on Protagonist Therapeutics in a research report on Tuesday, June 17th. They set a "buy" rating and a $72.00 price target on the stock. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $66.10.

Protagonist Therapeutics Trading Up 2.6%

PTGX opened at $55.15 on Friday. The company has a market cap of $3.42 billion, a P/E ratio of 73.53 and a beta of 2.26. The business's 50-day moving average price is $52.31 and its 200-day moving average price is $46.21. Protagonist Therapeutics, Inc. has a 12 month low of $32.50 and a 12 month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. Equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.